On November 8, 2012, Louisiana resident Mary Weeks chose to file a Pradaxa lawsuit against manufacturer Boehringer Ingelheim Pharmaceuticals alleging that she suffered from serious injuries after taking the anticoagulant medication. The case joins similar filings that have been consolidated into multidistrict litigation (MDL) located... Read More

Pradaxa is an anticoagulant, or a blood-thinning medication. As a class of drug known as a direct thrombin inhibitor, Pradaxa works by preventing the formation of blood clots. Patients suffering from atrial fibrillation—also known as irregular heartbeat—may be prescribed Pradaxa to prevent them from having... Read More

The grieving daughter of a woman who died of bleeding from Pradaxa has filed a lawsuit against the drug's manufacturer, Boehringer Ingelheim. The daughter, Jennifer Banks, filed the lawsuit both individually and as the administrator of the estate of Lydia Banks, her late mother, on... Read More

A lawsuit alleging side effects from Pradaxa was filed by plaintiff Harriet Meyer in August in the Eastern District of Kentucky. On October 1, 2012, the case was transferred to the U.S. District Court in Illinois where the Pradaxa multidistrict litigation (MDL) is located. An... Read More

Pradaxa is an anticoagulant drug used to treat patients with non-valvular atrial fibrillation, and can help reduce the risk of blood clots and strokes in these at-risk patients. Drug maker Boehringer Ingelheim introduced the drug in 2010, marketing it as a superior alternative to older... Read More

The wife of a man who died has chosen to file a Pradaxa lawsuit on his behalf. Mary Cornwell, a resident of Ohio, filed her case against Boehringer Ingelheim—the manufacturer of Pradaxa—in the U.S. District Court for the Southern District of Illinois on October 10,... Read More

The Institute for Safe Medicine Practices issued a warning for the blood thinner Xarelto at the beginning of October. The ISMP cited a higher than expected risk of blood clots associated with the medication, and the warning come shortly after one that the FDA issued... Read More

The first bellwether trials in the MDL for Pradaxa cases have been scheduled to begin in August 2014 – only two years after the establishment of the MDL, which is a relatively fast turnaround. That's good news for plaintiffs in the 120 Pradaxa cases pending... Read More